Navigation Links
Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest
Date:4/14/2008

- Faster delivery, efficient supply chain, and reduced cost for

pharmaceutical manufacturers

NEW YORK, April 14 /PRNewswire/ -- Sumitomo Corporation of America (SCOA) has reached an agreement with Chiral Quest, Inc., a manufacturer and developer of chiral products using proprietary chiral technologies, for the distribution and sale of chiral products to the pharmaceutical industry.

Effective immediately, Sumitomo will be the exclusive sales agent for Chiral Quest in Japan and selected worldwide accounts.

More than 40 percent of the ethical drugs manufactured today utilize chiral intermediate technology. Chiral chemocatalysts play a key role in the manufacture of medicines, fine chemicals, agricultural chemicals, and flavors and fragrances.

"Chiral Quest is now in an expansion phase, and Sumitomo's international network of marketing and distribution facilities will enable us to provide our specialty chiral molecules quickly to pharmaceutical manufacturers globally at competitive prices," said Dr. Joseph Marasco, CEO of Chiral Quest. "This is a venture that will be welcomed by the chiral molecule marketplace, and will allow us to efficiently serve our growing client base."

Chiral Quest has wholly owned patents on a range of innovative chemical catalysts and processes used in the synthesis of chiral molecules. The company's primary laboratory and manufacturing facilities in New Jersey and China will now be supported by Sumitomo's extensive marketing capability and distribution network. Additional information on Chiral Quest is available at their website http://www.chiralquest.com/.

"Sumitomo has been a major supplier to the global pharmaceutical industry for over the past four decades," noted Yasunori Ishibashi, senior director of the SCOA Medical Sciences Group. "This collaboration makes it possible for Sumitomo to play a significant role in the innovative and growing field of chiral technology."

Sumitomo's established supply chain provides chemicals for a range of manufacturing processes. The company's chemical experts help specific clients in the field select and implement the most efficient synthesis process for producing specific molecules.

The catalytic asymmetric hydrogenation process was discovered in 1987 by Dr. Ryoji Nyori. Over the past two decades, Nyori chiral technology has evolved rapidly and become widely applied in chemocatalysis. It has been especially valuable in the manufacture of chiral pharmaceutical products and fine chemicals. In 2001 Dr. Nyori shared the Nobel Prize in Chemistry with William S. Knowles for their work in the study of chirally catalyzed hydrogenation.

Sumitomo's global network includes 148 offices in 67 countries. Sumitomo also provides unique expertise in the import and export business.

Through its global network for sales and distribution, Sumitomo has become a major resource for pharmaceutical companies. Sumitomo provides raw materials, production facilities, R&D facilities and various technical process support to major manufacturers in the pharmaceutical industry.

About Sumitomo Corporation of America

Sumitomo Corporation of America (SCOA), is a fully integrated trading and investment enterprise with offices in 11 major U.S. cities. SCOA is the largest wholly owned subsidiary of Sumitomo Corporation (SC), an integrated global trading firm with diversified investments and businesses. Established in 1952, and headquartered in New York, SCOA is involved in a wide range of industries, including working on a global scale with SC and subsidiaries to expand on emerging opportunities in the pharmaceutical industry. http://www.sumitomocorp.com


'/>"/>
SOURCE Sumitomo Corporation of America
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
2. IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference
3. Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call
4. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
5. Chem Rx Corporation Reports Full Year 2007 Financial Results
6. Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results
7. Genaera Corporation Announces 2007 Financial Results
8. Chem Rx Corporation Schedules Conference Call to Review Full Year 2007 Financial Results
9. Immunosyn Corporation Announces 2007 Results, Files 10KSB
10. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
11. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from ... believe could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving ... to read it now. , Biomarkers are components in the blood, tissue ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):